Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value …,

Of note, amongst the clinically low risk study population, distant metastasis free survival at 8 years was 3.6% better in MammaPrint Low Risk patients …, Of note, amongst the clinically low risk study population, distant metastasis free survival at 8 years was 3.6% better in MammaPrint Low Risk patients …, Read More

Scroll to Top